No Data
No Data
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product
Optimistic Buy Rating for Terns Pharmaceuticals Amid Promising Clinical Progress and Solid Financial Footing
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)
Buy Rating Affirmed for Terns Pharmaceuticals Amid Robust Financials and Promising Pipeline Prospects
Express News | HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $5.5 Price Target
Terns Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 -6.62% HC Wainwright & Co. → $5.5 Reiterates Neutral → Neutral 04/30/2024 -6.62% HC Wainwright
No Data